Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?

Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?

Purpose of Review This review will explore various strategies to rendering MSS mCRCs susceptible to ICI. Moreover, we will provide an overview of potential biomarkers that may aid to better patient selection, and discuss ongoing efforts in this area of research. Recent Findings Colorectal cancer (CR...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports Vol. 26; no. 10; pp. 1258 - 1270
Main Authors: Hamid, Marwa Abdel, Pammer, Lorenz M., Lentner, Theresa K., Doleschal, Bernhard, Gruber, Rebecca, Kocher, Florian, Gasser, Elisabeth, Jöbstl, Anna, Seeber, Andreas, Amann, Arno
Format: Journal Article
Language:English
Published: New York Springer US 01-10-2024
Springer Nature B.V
Subjects:
Colorectal cancer
Colorectal carcinoma
Immune checkpoint inhibitors
Immunotherapy
Malignancy
Medicine
Medicine & Public Health
Metastases
Metastasis
Microsatellite instability
Oncology
Review
Topical Collection on Lower Gastrointestinal Cancers
Biomarker
Microsatellite instability
Microsatellite stable
Immunotherapy
Colorectal cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review This review will explore various strategies to rendering MSS mCRCs susceptible to ICI. Moreover, we will provide an overview of potential biomarkers that may aid to better patient selection, and discuss ongoing efforts in this area of research. Recent Findings Colorectal cancer (CRC) ranks among the top three most common cancers worldwide. While significant advances in treatment strategies have improved the prognosis for patients in the early stages of the disease, treatment options for metastatic CRC (mCRC) remain limited. Although immune checkpoint inhibitors (ICI) have revolutionized the treatment of several malignancies, its efficacy in mCRC is largely confined to patients exhibiting a high microsatellite instability status (MSI-H). However, the vast majority of mCRC patients do not exhibit a MSI-H, but are microsatellite stable (MSS). In these patients ICIs are largely ineffective. Summary So far, ICIs do not play a crucial role in patients with MSS mCRC, despite the promising data for inducing long-term remissions in other tumour entities. For this reason, novel treatment strategies are needed to overcome the primary resistance upon ICI in patients with MSS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1523-3790
1534-6269
1534-6269
DOI:10.1007/s11912-024-01583-w